Prevention of life-threatening ventricular tachyarrhythmia by a novel and pure class-III agent, nifekalant hydrochloride

Journal of Cardiovascular Pharmacology

Volumn 48, Issue 6, 2006, Pages 274-279

  Ohashi, Junko ^a   Yasuda, Satoshi ^a,b   Miyazaki, Shunichi ^a   Shimizu, Wataru ^a   Morii, Isao ^a   Kurita, Takashi ^a   Kawamura, Atsushi ^a   Kamakura, Shiro ^a   Nonogi, Hiroshi ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antiarrhythmia agents; Electrocardiography; Potassium; Tachyarrhythmia; Torsade de pointes

Indexed keywords

AMIODARONE; NIFEKALANT; SOTALOL;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HEMODYNAMICS; HUMAN; MALE; POTASSIUM TRANSPORT; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; TORSADE DES POINTES;

AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; HEART DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PYRIMIDINONES; RISK FACTORS; TREATMENT OUTCOME; VENTRICULAR FIBRILLATION;

EID: 33846102009     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000248242.99337.4d     Document Type: Article

References (18)

1. Ishii, M, Kamiya, J, Hashimoto K. Cellular electrophysiological effects of MS-551, a new class III antiarrhythmic agent. Drug Dev Res. 1995;35:61-68.
2. (R)injection), a class III antiarrhythmic drug. Folia Pharmacol Jpn. 2003;119:103-109.
3. Takenaka K, Yasuda S, Miyazaki S, et al. Initial experience with nifekalant hydrochloride (MS-551), a novel class III antiarrhythmic agent, in patients with acute extensive infarction and severe ventricular dysfunction. Jpn Circ J. 2001;65:60-62.
4. Myoishi M, Yasuda S, Miyazaki S, et al. Intravenous administration of nifekalant hydrochloride for the prevention of ischemia-induced ventricular tachyarrhythmia in patients with renal failure undergoing hemodialysis. Circ J. 2003;67:898-900.
5. Kondoh K, Hshimoto H, Nishiyama H, et al. Efeect of MS-551, a new class III antiarrhythmic drug on programmed stimulation-induced ventricular arrhythmias, electrophysiology, and hemodynamics in a canine myocardial infarction model. J Cardiovasc Pharmacol. 1994;23:674-680.
6. Sen L, Cui G, Sakaguchi Y, et al. Electrophysiological effects of MS-551, a new Class III agent: Comparison with dl-sotalol in dogs. J Pharmacol Exp Ther. 1998;285:687-694.
7. Sugiyama A, Satoh Y, Hashimoto K. Acute electropharmacological effects of intravenously administerd amiodarone assessed in the In Vivo canine model. Jpn J Pharmacol. 2001;87:74-82.
8. Masakawa Y, Yamashita T, Kanese Y, et al. Can a class III antiarrhythmic drug improve electrical defibrillation efficacy during ventricular fibrillation? J Am Coll Cardiol. 1997;29:688-692.
9. Huang J, Skinner JL, Rogers JM, et al. The effects of acute and chronic amiodarone on activation patterns and defibrillation threshold during ventricular fibrillation in dogs. J Am Coll Cardiol. 2002;40:375-383.
10. Guidelines 2005 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 7: Section 3: Management of Symptomatic Bradycardia and Tachycardia. The American Heart Association in collaboration with the international liaison committee on resuscitation. Circulation. 2005;112:67-77.
11. Shimizu W. Antzelevitch C. Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade de pointes in LQT2 and LQT3 models of the long QT syndrome. Circulation. 1997;96:2038-2047.
12. Scheinman MM, Levine JH, Cannom DS, et al. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group. Circulation. 1995;92:3264-3272.
13. Saul JP, Scott WA, Brown S, et al. Intravenous Amiodarone Pediatric Investigators. Intravenous amiodarone for incessant tachyarrhythmias in children: a randomized, double-blind, antiarrhythmic drug trial. Circulation. 2005;112:3470-3477.
14. Wit AL, Janse MJ. The Ventricular Arrhythmias of Ischemias and Infarction. Electrophysiological Mechanisms. New York: Futura Publishing, 1993:1-648.
15. van Opstal JM, Schoenmakers M, Verduyn SC, et al. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation. 2001;104:2722-2727.
16. Satoh Y, Sugiyama A, Takahara A, et al. Electropharmacological and proarrhythmic effects of a class III antiarrhythmic drug nifekalant hydrochloride assessed using the in vivo canine models. J Cardiovasc Pharmacol. 2004;43:715-722.
17. + current in heart: molecular basis, functional diversity, and contribution to repolarization. Acta Pharmacol. 2004;25:137-145.
18. Tahara Y, Kimura K, Kosuge M, et al. Comparison of nifekalant and lidocaine for the treatment of shock-refractory ventricular fibrillation. Circ J. 2006;70:442-446.